Increased hepatic and circulating interleukin-6 levels in human nonalcoholic steatohepatitis

American Journal of Gastroenterology

Volumn 103, Issue 12, 2008, Pages 3217-3218

  Dogru, Teoman ^a   Ercin, Cemal Nuri ^a   Erdem, Gokhan ^a   Sonmez, Alper ^a   Tapan, Serkan ^a   Tasci, Ilker ^a  

^a GULHANE SCHOOL OF MEDICINE   (Turkey)

Author keywords

[No Author keywords available]

Indexed keywords

GLUCOSE; INTERLEUKIN 6; BIOLOGICAL MARKER;

DIABETES MELLITUS; GLUCOSE BLOOD LEVEL; HUMAN; HYPERTENSION; IMPAIRED GLUCOSE TOLERANCE; LETTER; NONALCOHOLIC FATTY LIVER; OBESITY; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; STEATOSIS; FATTY LIVER; METABOLISM; NOTE; PATHOPHYSIOLOGY;

BIOLOGICAL MARKERS; FATTY LIVER; HUMANS; INTERLEUKIN-6;

EID: 58149402412     PISSN: 00029270     EISSN: 15720241     Source Type: Journal    
DOI: 10.1111/j.1572-0241.2008.02161_17.x     Document Type: Letter

References (5)

1. Wieckowska A, Papouchado BG, Li Z, et al. Increased hepatic and circulating interleukin-6 levels in human nonalcoholic steatohepatitis. Am J Gastroenterol 2008 103 : 1372 9.
2. Dandona P, Aljada A, Bandyopadhyay A. Inflammation: the link between insulin resistance, obesity and diabetes. Trends Immunol 2004 25 : 4 7.
3. Corpeleijn E, Saris WH, Jansen EH, et al. Postprandial interleukin-6 release from skeletal muscle in men with impaired glucose tolerance can be reduced by weight loss. J Clin Endocrinol Metab 2005 90 : 5819 24.
4. Tahan V, Eren F, Avsar E, et al. Rosiglitazone attenuates liver inflammation in a rat model of nonalcoholic steatohepatitis. Dig Dis Sci 2007 52 : 3465 72.
5. Toblli JE, Munoz MC, Cao G, et al. ACE inhibition and AT1 receptor blockade prevent fatty liver and fibrosis in obese Zucker rats. Obesity 2008 16 : 770 6.